Abstract |
A randomised double-blind controlled clinical trial was conducted to compare oral ciprofloxacin (500 mg b.d.) and amoxycillin (1 g t.d.s.) in the treatment of infective exacerbations of bronchiectasis. The commonest organism isolated from sputum was Pseudomonas aeruginosa, which accounted for 34% of all positive sputum cultures. Other Pseudomonas species and Haemophilus influenzae, accounted for 19%, respectively. Ciprofloxacin produced better clinical response, a higher sputum to serum antibiotic level (mean of 0.65 in the ciprofloxacin group vs. 0.18 in amoxycillin group, p = 0.0001), broader spectrum of antibacterial activity and less side-effect. It was also better tolerated by patients. The findings suggest that ciprofloxacin is an effective treatment of infective exacerbations of bronchiectasis.
|
Authors | T H Chan, S S Ho, C K Lai, S W Cheung, R C Chan, A F Cheng, C H Chan |
Journal | Chemotherapy
(Chemotherapy)
1996 Mar-Apr
Vol. 42
Issue 2
Pg. 150-6
ISSN: 0009-3157 [Print] Switzerland |
PMID | 8697891
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Infective Agents
- Penicillins
- Ciprofloxacin
- Amoxicillin
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Amoxicillin
(therapeutic use)
- Anti-Infective Agents
(therapeutic use)
- Bacterial Infections
(drug therapy)
- Bronchiectasis
(drug therapy)
- Ciprofloxacin
(therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Penicillins
(therapeutic use)
|